MUC5B promoter polymorphism and pulmonary fibrosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-β and the Ubiquitin-Proteasome Pathway.International journal of molecular sciences · 2021
   Review
2. MUC5B promoter polymorphisms and risk of coal workers' pneumoconiosis in a Chinese population.Molecular biology reports · 2014
   Article
3. Association between MUC5B and TERT polymorphisms and different interstitial lung disease phenotypes.Translational research : the journal of laboratory and clinical medicine · 2014
   Article

Corrections and comments

• Comment on
  A common MUC5B promoter polymorphism and pulmonary fibrosis.2011

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as